IDEX BIOMETRICS ASA
Two primary insiders in IDEX Biometrics ASA acquired IDEX ADSs, Nasdaq ticker code IDBA, on 1 March 2021. One ADS (IDBA) represents 75 ordinary shares (IDEX). The ordinary shares in IDEX are listed on Oslo Børs, ticker code IDEX.
CEO Vince Graziani acquired 2,000 ADSs, which corresponds to 150,000 ordinary shares, at an average price of USD 28.80 per ADS.. After the transaction, Mr. Graziani holds the equivalent of 960,239 ordinary shares and 5,000,000 incentive subscription rights to ordinary shares in IDEX.
CFO Derek D’Antilio acquired 500 ADSs, which represent 37,500 ordinary shares, at an average price of USD 31.50 per ADS. After the transaction, Mr. D’Antilio holds the equivalent of 795,426 ordinary shares and 2,000,000 incentive subscription rights to ordinary shares in IDEX.
For further information contact:
Marianne Bøe, Investor Relations
E-mail: marianne.boe@idexbiometrics.com
Tel: + 47 918 00186
Derek D’Antilio, Chief Financial Officer
E-mail: derek.dantilio@idexbiometrics.com
Tel: +1 978 273 1344
About IDEX Biometrics
IDEX Biometrics ASA (OSE: IDEX and Nasdaq: IDBA) is a leading provider of fingerprint identification technologies offering simple, secure, and personal touch-free authentication for all. We help people make payments, prove their identity, gain access to information, unlock devices, or gain admittance to buildings with the touch of a finger. We invent, engineer, and commercialize these secure, yet incredibly user-friendly solutions. Our total addressable market represents a fast growing multi-billion-unit opportunity.
For more information, visit www.idexbiometrics.com and follow @IDEXBiometrics
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Novo Nordisk A/S6.11.2025 19:00:56 CET | Press release
Novo Nordisk announces agreement with the U.S. Administration to bring GLP-1s to more Americans at a lower cost
BONDUELLE6.11.2025 18:00:00 CET | Press release
BONDUELLE - Quarter 1 FY 2025-2026 Sales: The Bonduelle Group confirms its resilience in a demanding environment
Verkkokauppa.com Oyj6.11.2025 18:00:00 CET | Press release
Verkkokauppa.com Oyj: Acquisition of own shares on 6 November 2025
Vivoryon Therapeutics N.V.6.11.2025 17:31:00 CET | Press release
Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025
Aspo Plc6.11.2025 17:30:00 CET | Press release
Aspo Plc: Share repurchase 6.11.2025
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
